《大行》花旗升和铂医药(02162.HK)目标价至85元 评级“买入”

阿斯达克财经
Aug 29, 2025

花旗发表示研究报告指,和铂医药-B(02162.HK) 上半年收入达4.99亿元人民币(下同),列账净亏损收窄至约7,900万元,对上财年同期蚀3.37亿元。该行认为,CM310今年商业化不确定性的担忧正在消退,而CM512(TSLP/IL-13 双特异性)等新候选药物已引起更多关注。该行表示,将其今年收入预测由原先6.92亿元上调至8.29亿元,同时将今年、明年及2027年每股盈测上调至亏损...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10